Stifel maintains $166 target on Neurocrine Bio shares

Stifel analysts reiterated a Buy rating with a $166 price target on Neurocrine Biosciences (NBIX), citing positive discussions with CEO Dr. Kyle Gano and confidence in the company's trajectory after a strong end to Q1, despite initial hurdles. The optimism is further supported by 21.7% revenue growth over the last twelve months and the potential of their research pipeline, including the AMPA program and NR2B-NAM. Recent data from Phase 3 and 4 studies on CRENESSITY and INGREZZA, respectively, have also contributed to positive analyst evaluations, with Cantor Fitzgerald maintaining an Overweight rating and UBS raising its price target.

Analysis

Stifel analysts have reaffirmed their Buy rating and $166.00 price target for Neurocrine Biosciences (NBIX), reflecting broader Wall Street optimism, as InvestingPro data indicates eight analysts recently revised earnings estimates upward. This positive stance is reinforced by discussions with Neurocrine's CEO, Dr. Kyle Gano, who conveyed satisfaction with the strong conclusion to the first quarter, projecting continued momentum despite initial challenges. Neurocrine's financial health is rated "GREAT" by InvestingPro, underpinned by robust revenue growth of 21.7% over the last twelve months and moderate debt levels; InvestingPro analysis also suggests the stock, trading at $121.62 with a $12 billion market capitalization, is currently undervalued. While the key treatment Ingrezza encountered some hurdles, its end-of-Q1 performance has bolstered management confidence. The newer treatment, Crenessity, is in its early patient acquisition phase, with an anticipated evolution in patient demographics, potentially skewing towards pediatric patients. The company's exposure to market forces (MFN) is currently limited, as Ingrezza is only sold in Japan outside the U.S., and there are no immediate plans for a European launch of Crenessity. Significant enthusiasm surrounds the research pipeline, especially the AMPA program and NR2B-NAM, the latter of which is expected to deliver data later this year. Recent positive clinical trial results further support this outlook: a Phase 3 study demonstrated CRENESSITY's efficacy in reducing glucocorticoid doses for children with classic congenital adrenal hyperplasia, and a Phase 4 study showed INGREZZA improved quality of life for patients with tardive dyskinesia. These developments have prompted favorable evaluations from other analyst firms, including Cantor Fitzgerald, which maintained an Overweight rating with a $170 target, and UBS, which raised its price target to $152 while reiterating a Buy rating, both citing strong demand and revenue prospects for Ingrezza and CRENESSITY.

Key Decisions for Investors

• The consistent positive analyst ratings from Stifel, Cantor Fitzgerald, and UBS, coupled with Neurocrine's 21.7% LTM revenue growth and management's optimistic outlook following a strong Q1 finish, support a constructive view on the stock.
• Investors should closely monitor upcoming clinical data from the NR2B-NAM program, expected later this year, as this represents a significant potential catalyst, and also track the patient uptake and demographic mix for the newly launched Crenessity.
• While InvestingPro data suggests the stock is undervalued and reflects strong financial health, an article note indicating NBIX was not a top AI-driven pick warrants a balanced perspective, underscoring the importance of comprehensive due diligence alongside the prevailing bullish analyst sentiment.